Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Recruiting 4Active not recruiting 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 115Carcinoma, Non-Small-Cell Lung 103Prostatic Neoplasms 90Neoplasms 74Multiple Myeloma 73Lung Neoplasms 64Colorectal Neoplasms 50Leukemia, Myeloid, Acute 46Neoplasm Metastasis 43Lymphoma 39Pancreatic Neoplasms 38Melanoma 38Lymphoma, Non-Hodgkin 36Carcinoma, Renal Cell 36Ovarian Neoplasms 34Leukemia, Lymphocytic, Chronic, B-Cell 33Squamous Cell Carcinoma of Head and Neck 31Urinary Bladder Neoplasms 30Hematologic Neoplasms 28Precursor Cell Lymphoblastic Leukemia-Lymphoma 26Endometrial Neoplasms 26Uterine Cervical Neoplasms 25Carcinoma, Hepatocellular 25Triple Negative Breast Neoplasms 24Sarcoma 24Glioma 24Stomach Neoplasms 22Head and Neck Neoplasms 22Lymphoma, Large B-Cell, Diffuse 21Brain Neoplasms 21

Interventions

pertuzumab 2atezolizumab 1Trastuzumab 1Paclitaxel 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × HER2-positive Breast Cancer × 30 days × Clear all
NCT03125928 2026-05-22

Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer

Fox Chase Cancer Center

Phase 2 Active not recruiting
16 enrolled
Breast

HER2-positive Breast Cancer

NCT06445400 2026-05-13

A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 2 Active not recruiting
83 enrolled
Breast

HER2-positive Breast Cancer

NCT06968585 2026-05-08

A166

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Phase 3 Active not recruiting
365 enrolled
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡